Fulvestrant is a selective estrogen receptor down-regulator endocrine drug that can completely inhibit estrogen receptor signaling and downstream signaling pathways, preventing estrogen from binding to tumor cells (5). The gene discussed is ESR1; the disease is neoplasm.